Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Lebrikizumab
Drug: Standard of Care
Drug: Placebo

First Posted Date: 2013-06-11

Last Posted Date: 2017-05-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 348

Registration Number: NCT01875003

Locations: 🇺🇸
Allergy & Asthma Consultants, Redwood City, California, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
The Clinical Research Center, Shiloh, Illinois, United States

and more 161 locations

A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO4917523

First Posted Date: 2013-06-10

Last Posted Date: 2015-09-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT01873508

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Alectinib

First Posted Date: 2013-06-07

Last Posted Date: 2018-08-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 134

Registration Number: NCT01871805

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, Commack, New York, United States
🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCLA, Los Angeles, California, United States

and more 39 locations

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Lebrikizumab
Drug: Pirfenidone
Drug: Placebo

First Posted Date: 2013-06-07

Last Posted Date: 2018-08-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 505

Registration Number: NCT01872689

Locations: 🇺🇸
Pulmonary Consultants, Tacoma, Washington, United States
🇦🇺
Box Hill Hospital; Eastern Clinical Research Unit, Box Hill, Victoria, Australia
🇫🇷
Hopital Bichat Claude Bernard ; Service de Pneumologie, Paris, France

and more 109 locations

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: placebo
Drug: aleglitazar

First Posted Date: 2013-06-06

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 13

Registration Number: NCT01871428

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: aleglitazar
Drug: placebo
Drug: metformin

First Posted Date: 2013-06-06

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 7

Registration Number: NCT01871415

A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Lebrikizumab
Drug: Placebo

First Posted Date: 2013-06-04

Last Posted Date: 2017-05-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1068

Registration Number: NCT01868061

Locations: 🇵🇱
NZOZ Lekarze Specjalisci, Wroclaw, Poland
🇸🇰
ZAPA JJ Sro, Levice, Slovakia
🇺🇸
Allergy Consultants PA, Boca Raton, Florida, United States

and more 229 locations

A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Lebrikizumab
Drug: Placebo

First Posted Date: 2013-06-03

Last Posted Date: 2017-05-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1081

Registration Number: NCT01867125

Locations: 🇺🇸
Choc Psf, Amc, Orange, California, United States
🇺🇸
North Bay Clinical Trials, Napa, California, United States
🇺🇸
Bensch Research Associates, Stockton, California, United States

and more 227 locations

A Retrospective, Observational Chart Review of Biologics in Monotherapy Versus the Combination Biologic Plus Methotrexate in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2013-05-31

Last Posted Date: 2015-10-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 476

Registration Number: NCT01866150

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)

Completed

Conditions: Ovarian Cancer

First Posted Date: 2013-05-29

Last Posted Date: 2018-09-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 300

Registration Number: NCT01863693

Locations: 🇬🇧
Queen Alexandra Hospital; Portsmouth Haematology & Oncology Centre, Level B, Portsmouth, United Kingdom
🇬🇧
Royal United Hospital; Oncology Department, Bath, United Kingdom
🇬🇧
Eastborne District General Hospital, Eastbourne, United Kingdom

and more 27 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy